Search

Background The aim of this study was to determine the effect of anatomic resection (AR) versus non-anatomic resection (NAR) on recurrence rates in patients with hepatocellular carcinoma (HCC). Methods Eligible patients were randomized to AR or NAR from January 2006 to July 2007 at a single center. The primary outcome was the 2-year recurrence-free survival (RFS). Secondary outcomes were postoperative complications, time to first recurrence, 1-, 3-, and 5-year RFS, and overall survival (OS). Results Fifty-three (51%) and 52 (50%) patients underwent NAR and AR, respectively. A larger proportion of patients achieved margins ≥20 mm in the AR group (52% vs. 30%; P = 0.023). Complications (blood loss, transfusion requirement, and hospital stay) were similar between the two groups. Median follow-up was 33 (range, 2–77) months. Incidence of local recurrence at 2 years was 30% and 59% in the AR and NAR groups, respectively. Median time to first local recurrence in the AR group was significantly longer than in the NAR group (53 vs. 10 months, P = 0.010). There was no difference in overall RFS between the two groups (P = 0.290). Discussion AR decreased the 2-year local recurrence rate and increased the time to first local recurrence compared to NAR in patients with HCC. [ABSTRACT FROM AUTHOR]

Highlights: [•] HDAC inhibitors suppress cell growth and self-renewal of liver CSCs. [•] HDAC3 is selectively expressed in liver CSCs and participates in self-renewal of liver CSCs. [•] HDAC3 regulates expression of pluripotency factors through histone modification. [•] Overexpression of HDAC3 is associated with poor outcome of liver cancer. [•] HDAC inhibitors render liver CSCs sensitive to sorafenib. [Copyright &y& Elsevier]